{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:40:01Z","timestamp":1748907601500,"version":"3.41.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00403-016-1647-6","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T13:50:35Z","timestamp":1462024235000},"page":"461-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current and future direction in the management of scleroderma"],"prefix":"10.1007","volume":"308","author":[{"given":"Sean M.","family":"Brady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,30]]},"reference":[{"key":"1647_CR1","unstructured":"Assistance Publique\u2014H\u00f4pitaux de Paris (2015) Effect of bosentan in scleroderma renal crisis (ScS-REINBO): NCT01241383. Available via Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01241383?term=scleroderma+renal+crisis+bosentan&rank=1 . Accessed 24 Nov 2015"},{"key":"1647_CR2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/gt.2011.159","volume":"19","author":"I Badea","year":"2012","unstructured":"Badea I, Virtanen C, Verrall RE, Rosenberg A, Foldvari M (2012) Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk\/+ mice. Gene Ther 19:978\u2013987","journal-title":"Gene Ther"},{"key":"1647_CR3","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417\u20132422","journal-title":"J Rheumatol"},{"key":"1647_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425\u2013434","journal-title":"Ann Intern Med"},{"key":"1647_CR5","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667\u20132676","journal-title":"N Engl J Med"},{"key":"1647_CR6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296\u2013301","journal-title":"N Engl J Med"},{"key":"1647_CR7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","volume":"121","author":"RJ Barst","year":"1994","unstructured":"Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121:409\u2013415","journal-title":"Ann Intern Med"},{"key":"1647_CR8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ad.2012.10.003","volume":"104","author":"I Bielsa Marsol","year":"2013","unstructured":"Bielsa Marsol I (2013) Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr 104:654\u2013666","journal-title":"Actas Dermosifiliogr"},{"key":"1647_CR9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2003.11.003","volume":"34","author":"Y Braun-Moscovici","year":"2004","unstructured":"Braun-Moscovici Y, Nahir AM, Balbir-Gurman A (2004) Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 34:442\u2013453","journal-title":"Semin Arthritis Rheum"},{"key":"1647_CR10","first-page":"14","volume":"12","author":"C Cantisani","year":"2013","unstructured":"Cantisani C, Miraglia E, Richetta AG, Mattozzi C, Calvieri S (2013) Generalized morphea successfully treated with tacrolimus 0.1\u00a0% ointment. J Drugs Dermatol 12:14\u201315","journal-title":"J Drugs Dermatol"},{"key":"1647_CR11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","volume":"9","author":"FV Castelino","year":"2013","unstructured":"Castelino FV, Varga J (2013) Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol 9:1077\u20131090","journal-title":"Expert Rev Clin Immunol"},{"key":"1647_CR12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40:1038\u20131043","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/annrheumdis-2012-202849","volume":"73","author":"TR Cottrell","year":"2014","unstructured":"Cottrell TR, Wise RA, Wigley FM, Boin F (2014) The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 73:1060\u20131066","journal-title":"Ann Rheum Dis"},{"key":"1647_CR14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0190-9622(98)70077-5","volume":"39","author":"BB Cunningham","year":"1998","unstructured":"Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS (1998) Topical calcipotriene for morphea\/linear scleroderma. J Am Acad Dermatol 39:211\u2013215","journal-title":"J Am Acad Dermatol"},{"key":"1647_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1183\/09059180.00006111","volume":"20","author":"CP Denton","year":"2011","unstructured":"Denton CP, Hachulla E (2011) Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 20:270\u2013276","journal-title":"Eur Respir Rev"},{"key":"1647_CR16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","volume":"48","author":"CT Derk","year":"2009","unstructured":"Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595\u20131599","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR17","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.lpm.2014.08.001","volume":"43","author":"N Dumoitier","year":"2014","unstructured":"Dumoitier N, Lofek S, Mouthon L (2014) Pathophysiology of systemic sclerosis: state of the art in 2014. Presse Med 43:e267\u2013e278","journal-title":"Presse Med"},{"key":"1647_CR18","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"1647_CR19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00109-014-1190-x","volume":"92","author":"B Eckes","year":"2014","unstructured":"Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T (2014) Molecular and cellular basis of scleroderma. J Mol Med (Berl) 92:913\u2013924","journal-title":"J Mol Med (Berl)"},{"key":"1647_CR20","first-page":"002069","volume":"1","author":"H Ennis","year":"2014","unstructured":"Ennis H, Anderson ME, Wilkinson J, Herrick AL (2014) Calcium channel blockers for primary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev 1:002069","journal-title":"Cochrane Database Syst Rev"},{"key":"1647_CR21","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894\u20132903","journal-title":"Circulation"},{"key":"1647_CR22","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Galie","year":"2008","unstructured":"Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010\u20133019","journal-title":"Circulation"},{"key":"1647_CR23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.nano.2014.12.003","volume":"11","author":"M Gharagozloo","year":"2015","unstructured":"Gharagozloo M, Majewski S, Foldvari M (2015) Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction. Nanomedicine 11:1003\u20131018","journal-title":"Nanomedicine"},{"key":"1647_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330\u2013340","journal-title":"N Engl J Med"},{"key":"1647_CR25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar4230","volume":"15","author":"AJ Gilbane","year":"2013","unstructured":"Gilbane AJ, Denton CP, Holmes AM (2013) Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 15:215","journal-title":"Arthritis Res Ther"},{"key":"1647_CR26","first-page":"911","volume":"13","author":"M Giordano","year":"1986","unstructured":"Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13:911\u2013916","journal-title":"J Rheumatol"},{"key":"1647_CR27","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/jps.24193","volume":"103","author":"N Gupta","year":"2014","unstructured":"Gupta N, Ibrahim HM, Ahsan F (2014) Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension. J Pharm Sci 103:3743\u20133753","journal-title":"J Pharm Sci"},{"key":"1647_CR28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/rheumatology\/ket421","volume":"53","author":"AL Herrick","year":"2014","unstructured":"Herrick AL, Murray AK, Ruck A, Rouru J, Moore TL, Whiteside J, Hakulinen P, Wigley F, Snapir A (2014) A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford) 53:948\u2013952","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","volume":"63","author":"AL Herrick","year":"2011","unstructured":"Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O\u2019Connell D, Vazquez-Abad MD, Denton CP (2011) Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63:775\u2013782","journal-title":"Arthritis Rheum"},{"key":"1647_CR30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis\u2014a lethal component of systemic sclerosis. Nat Rev Rheumatol 10:390\u2013402","journal-title":"Nat Rev Rheumatol"},{"key":"1647_CR31","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1111\/j.1742-4658.2005.05016.x","volume":"272","author":"A Horstmeyer","year":"2005","unstructured":"Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T (2005) Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 272:6297\u20136309","journal-title":"FEBS J"},{"key":"1647_CR32","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970","journal-title":"Arthritis Rheum"},{"key":"1647_CR33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 43:666\u2013672","journal-title":"Semin Arthritis Rheum"},{"key":"1647_CR34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejpb.2012.11.023","volume":"84","author":"V Ivanova","year":"2013","unstructured":"Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T (2013) Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm 84:335\u2013344","journal-title":"Eur J Pharm Biopharm"},{"key":"1647_CR35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","volume":"127","author":"ZC Jing","year":"2013","unstructured":"Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ (2013) Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 127:624\u2013633","journal-title":"Circulation"},{"key":"1647_CR36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194","journal-title":"Ann Rheum Dis"},{"key":"1647_CR37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","volume":"40","author":"GJ Keir","year":"2012","unstructured":"Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA (2012) Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 40:641\u2013648","journal-title":"Eur Respir J"},{"key":"1647_CR38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353\u2013359","journal-title":"Respirology"},{"key":"1647_CR39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/annrheumdis-2015-eular.1913","volume":"74","author":"D Khanna","year":"2015","unstructured":"Khanna D, Albera C, Fischer A, Seibold JR, Raghu G, Khalidi N, Chung L, Schiopu E, Chen D, Gorina E (2015) SAT0433 safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease\u2014the Lotuss study. Ann Rheum Dis 74:816","journal-title":"Ann Rheum Dis"},{"key":"1647_CR40","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","volume":"16","author":"A Kill","year":"2014","unstructured":"Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, Riemekasten G (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16:R29","journal-title":"Arthritis Res Ther"},{"key":"1647_CR41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/BOR.0000000000000117","volume":"26","author":"DF Kirby","year":"2014","unstructured":"Kirby DF, Chatterjee S (2014) Evaluation and management of gastrointestinal manifestations in scleroderma. Curr Opin Rheumatol 26:621\u2013629","journal-title":"Curr Opin Rheumatol"},{"key":"1647_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccm.2006.12.002","volume":"28","author":"JR Klinger","year":"2007","unstructured":"Klinger JR (2007) The nitric oxide\/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28:143\u2013167 (ix)","journal-title":"Clin Chest Med"},{"key":"1647_CR43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1529-8019.2012.01479.x","volume":"25","author":"A Kreuter","year":"2012","unstructured":"Kreuter A (2012) Localized scleroderma. Dermatol Ther 25:135\u2013147","journal-title":"Dermatol Ther"},{"key":"1647_CR44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1525-1470.2001.018003241.x","volume":"18","author":"A Kreuter","year":"2001","unstructured":"Kreuter A, Gambichler T, Avermaete A, Jansen T, Hoffmann M, Hoffmann K, Altmeyer P, von Kobyletzki G, Bacharach-Buhles M (2001) Combined treatment with calcipotriol ointment and low-dose ultraviolet al phototherapy in childhood morphea. Pediatr Dermatol 18:241\u2013245","journal-title":"Pediatr Dermatol"},{"key":"1647_CR45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","volume":"54","author":"A Kreuter","year":"2006","unstructured":"Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T (2006) A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54:440\u2013447","journal-title":"J Am Acad Dermatol"},{"key":"1647_CR46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","volume":"10","author":"EB Kroft","year":"2009","unstructured":"Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM (2009) Efficacy of topical tacrolimus 0.1\u00a0% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10:181\u2013187","journal-title":"Am J Clin Dermatol"},{"key":"1647_CR47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/NOR.0000000000000212","volume":"35","author":"KD Lachner","year":"2016","unstructured":"Lachner KD (2016) Caring for the patient with limited systemic scleroderma. Orthop Nurs 35:5\u201310","journal-title":"Orthop Nurs"},{"key":"1647_CR48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1183\/09031936.00058409","volume":"34","author":"A Lavelle","year":"2009","unstructured":"Lavelle A, Sugrue R, Lawler G, Mulligan N, Kelleher B, Murphy DM, Gaine SP (2009) Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 34:770\u2013771","journal-title":"Eur Respir J"},{"key":"1647_CR49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","volume":"18","author":"RM Laxer","year":"2006","unstructured":"Laxer RM, Zulian F (2006) Localized scleroderma. Curr Opin Rheumatol 18:606\u2013613","journal-title":"Curr Opin Rheumatol"},{"key":"1647_CR50","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816\u2013827","journal-title":"FASEB J"},{"key":"1647_CR51","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"1647_CR52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-94-007-4549-0_19","volume":"756","author":"K Lewandowska","year":"2013","unstructured":"Lewandowska K, Ciurzynski M, Gorska E, Bienias P, Irzyk K, Siwicka M, Zycinska K, Pruszczyk P, Demkow U (2013) Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis. Adv Exp Med Biol 756:147\u2013153","journal-title":"Adv Exp Med Biol"},{"key":"1647_CR53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2004.06318.x","volume":"152","author":"G Mancuso","year":"2005","unstructured":"Mancuso G, Berdondini RM (2005) Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 152:180\u2013182","journal-title":"Br J Dermatol"},{"key":"1647_CR54","first-page":"S5","volume":"22","author":"HR Maricq","year":"2004","unstructured":"Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22:S5\u2013S13","journal-title":"Clin Exp Rheumatol"},{"key":"1647_CR55","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","volume":"48","author":"G Martini","year":"2009","unstructured":"Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F (2009) Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 48:1410\u20131413","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"1647_CR57","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953\u20131962","journal-title":"Arthritis Rheum"},{"key":"1647_CR58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/13543784.2014.848852","volume":"23","author":"ZH McMahan","year":"2014","unstructured":"McMahan ZH, Wigley FM (2014) Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 23:183\u2013198","journal-title":"Expert Opin Investig Drugs"},{"key":"1647_CR59","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241\u20131247","journal-title":"J Rheumatol"},{"key":"1647_CR60","first-page":"235","volume":"31","author":"Y Miura","year":"2014","unstructured":"Miura Y, Saito T, Fujita K, Tanaka T, Tsunoda Y, Azuma A, Nei T, Yatagai Y, Rin S, Sekine A, Hayashihara K (2014) Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 31:235\u2013238","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"1647_CR61","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.131210","volume":"41","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Bussone G, Berezne A, Noel LH, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41:1040\u20131048","journal-title":"J Rheumatol"},{"key":"1647_CR62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14740338.2014.872238","volume":"13","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Spano F, Puppo F (2014) Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf 13:295\u2013305","journal-title":"Expert Opin Drug Saf"},{"key":"1647_CR63","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124","journal-title":"Arthritis Res Ther"},{"key":"1647_CR64","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","volume":"46","author":"SI Nihtyanova","year":"2007","unstructured":"Nihtyanova SI, Brough GM, Black CM, Denton CP (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2013a retrospective analysis. Rheumatology (Oxford) 46:442\u2013445","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR65","first-page":"156","volume":"32","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Ong VH, Denton CP (2014) Current management strategies for systemic sclerosis. Clin Exp Rheumatol 32:156\u2013164","journal-title":"Clin Exp Rheumatol"},{"key":"1647_CR66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0000000000000027","volume":"26","author":"M Nikpour","year":"2014","unstructured":"Nikpour M, Baron M (2014) Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 26:131\u2013137","journal-title":"Curr Opin Rheumatol"},{"key":"1647_CR67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/CS20130367","volume":"126","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly S (2014) Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 126:329\u2013337","journal-title":"Clin Sci (Lond)"},{"key":"1647_CR68","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322\u2013329","journal-title":"N Engl J Med"},{"key":"1647_CR69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","volume":"60","author":"RJ Oudiz","year":"2012","unstructured":"Oudiz RJ, Brundage BH, Galie N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ (2012) Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 60:768\u2013774","journal-title":"J Am Coll Cardiol"},{"key":"1647_CR70","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54:1971\u20131981","journal-title":"J Am Coll Cardiol"},{"key":"1647_CR71","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","volume":"106","author":"H Penn","year":"2013","unstructured":"Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, Denton CP (2013) Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106:839\u2013848","journal-title":"QJM"},{"key":"1647_CR72","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4065\/70.11.1068","volume":"70","author":"LS Peterson","year":"1995","unstructured":"Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc 70:1068\u20131076","journal-title":"Mayo Clin Proc"},{"key":"1647_CR73","first-page":"73","volume":"24","author":"LS Peterson","year":"1997","unstructured":"Peterson LS, Nelson AM, Su WP, Mason T, O\u2019Fallon WM, Gabriel SE (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960\u20131993. J Rheumatol 24:73\u201380","journal-title":"J Rheumatol"},{"key":"1647_CR74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000335560","volume":"223","author":"E Pope","year":"2011","unstructured":"Pope E, Doria AS, Theriault M, Mohanta A, Laxer RM (2011) Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology 223:363\u2013369","journal-title":"Dermatology"},{"key":"1647_CR75","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O\u2019Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351\u20131358","journal-title":"Arthritis Rheum"},{"key":"1647_CR76","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809\u2013818","journal-title":"N Engl J Med"},{"key":"1647_CR77","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","volume":"9","author":"B Ranque","year":"2010","unstructured":"Ranque B, Mouthon L (2010) Geoepidemiology of systemic sclerosis. Autoimmun Rev 9:A311\u2013A318","journal-title":"Autoimmun Rev"},{"key":"1647_CR78","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s13075-014-0510-4","volume":"16","author":"M Rodriguez-Castellanos","year":"2014","unstructured":"Rodriguez-Castellanos M, Tlacuilo-Parra A, Sanchez-Enriquez S, Velez-Gomez E, Guevara-Gutierrez E (2014) Pirfenidone gel in patients with localized scleroderma: a phase II study. Arthritis Res Ther 16:510","journal-title":"Arthritis Res Ther"},{"key":"1647_CR79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Z Rosman","year":"2013","unstructured":"Rosman Z, Shoenfeld Y, Zandman-Goddard G (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11:88","journal-title":"BMC Med"},{"key":"1647_CR80","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896\u2013903","journal-title":"N Engl J Med"},{"key":"1647_CR81","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","volume":"140","author":"LJ Rubin","year":"2011","unstructured":"Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140:1274\u20131283","journal-title":"Chest"},{"key":"1647_CR82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","volume":"112","author":"LJ Rubin","year":"1990","unstructured":"Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485\u2013491","journal-title":"Ann Intern Med"},{"key":"1647_CR83","unstructured":"Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS): NCT01933334 (2014) Available via Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01933334?term=pirfenidone&rank=5 . Accessed 16 Nov 2015"},{"key":"1647_CR84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF00371923","volume":"283","author":"K Scharffetter","year":"1991","unstructured":"Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, Krieg T, Plewig G (1991) UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 283:506\u2013511","journal-title":"Arch Dermatol Res"},{"key":"1647_CR85","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","volume":"36","author":"E Schiopu","year":"2009","unstructured":"Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR (2009) Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis. J Rheumatol 36:2264\u20132268","journal-title":"J Rheumatol"},{"key":"1647_CR86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/rheumatology\/27.4.286","volume":"27","author":"A Silman","year":"1988","unstructured":"Silman A, Jannini S, Symmons D, Bacon P (1988) An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 27:286\u2013290","journal-title":"Br J Rheumatol"},{"key":"1647_CR87","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Williams PG, Beghetti M, Corris P, Pepke-Zaba J, Souza R, DeMets DL, Gomberg-Maitland M, Greenberg BH, Schulman S, Douketis J, Investigators G (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522\u20132533","journal-title":"N Engl J Med"},{"key":"1647_CR88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.120778","volume":"40","author":"V Smith","year":"2013","unstructured":"Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52\u201357","journal-title":"J Rheumatol"},{"key":"1647_CR89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193\u2013197","journal-title":"Ann Rheum Dis"},{"key":"1647_CR90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"VD Steen","year":"1990","unstructured":"Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352\u2013357","journal-title":"Ann Intern Med"},{"key":"1647_CR91","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1346-8138.2008.00552.x","volume":"35","author":"C Stefanaki","year":"2008","unstructured":"Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, Gregoriou S, Katsambas A (2008) Topical tacrolimus 0.1\u00a0% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 35:712\u2013718","journal-title":"J Dermatol"},{"key":"1647_CR92","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1128\/MCB.9.11.5169","volume":"9","author":"B Stein","year":"1989","unstructured":"Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P (1989) UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol 9:5169\u20135181","journal-title":"Mol Cell Biol"},{"key":"1647_CR93","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581\u2013590","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"1647_CR94","first-page":"iii52","volume":"45","author":"C Sunderkotter","year":"2006","unstructured":"Sunderkotter C, Kuhn A, Hunzelmann N, Beissert S (2006) Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology (Oxford) 45(Suppl 3):iii52\u2013iii54","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","volume":"146","author":"DB Taichman","year":"2014","unstructured":"Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB (2014) Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146:449\u2013475","journal-title":"Chest"},{"key":"1647_CR96","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"1647_CR97","doi-asserted-by":"crossref","first-page":"505101","DOI":"10.1088\/0957-4484\/23\/50\/505101","volume":"23","author":"R Trivedi","year":"2012","unstructured":"Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB (2012) Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 23:505101","journal-title":"Nanotechnology"},{"key":"1647_CR98","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00403-014-1466-6","volume":"306","author":"A Usategui","year":"2014","unstructured":"Usategui A, Criado G, Del Rey MJ, Fare R, Pablos JL (2014) Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma. Arch Dermatol Res 306:757\u2013761","journal-title":"Arch Dermatol Res"},{"key":"1647_CR99","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"1647_CR100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Hoogen van den","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial. Br J Rheumatol 35:364\u2013372","journal-title":"Br J Rheumatol"},{"key":"1647_CR101","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","volume":"45","author":"F Zulian","year":"2006","unstructured":"Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, Cuttica R, Higgins GC, Van Suijlekom-Smit LW, Moore TL, Lindsley C, Garcia-Consuegra J, Esteves Hilario MO, Lepore L, Silva CA, Machado C, Garay SM, Uziel Y, Martini G, Foeldvari I, Peserico A, Woo P, Harper J (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45:614\u2013620","journal-title":"Rheumatology (Oxford)"},{"key":"1647_CR102","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, Alessio M, La Torre F, Podda RA, Gerloni V, Cutrone M, Belloni-Fortina A, Paradisi M, Martino S, Perilongo G (2011) Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63:1998\u20132006","journal-title":"Arthritis Rheum"},{"key":"1647_CR103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","volume":"65","author":"BA Zwischenberger","year":"2011","unstructured":"Zwischenberger BA, Jacobe HT (2011) A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 65:925\u2013941","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-016-1647-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-016-1647-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-016-1647-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:20:15Z","timestamp":1748906415000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-016-1647-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,30]]},"references-count":103,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s00403-016-1647-6","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"type":"print","value":"0340-3696"},{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2016,4,30]]}}}